Phase I Clinical Trial of Prostate-Specific Membrane Antigen-Targeting (68)Ga-NGUL PET/CT in Healthy Volunteers and Patients with Prostate Cancer

OBJECTIVE: (68)Ga-NGUL is a novel prostate-specific membrane antigen (PSMA)-targeting tracer based on Glu-Urea-Lys derivatives conjugated to a 1,4,7-triazacyclononane-N, N′, N″-triacetic acid (NOTA) chelator via a thiourea-type short linker. This phase I clinical trial of (68)Ga-NGUL was conducted t...

Descripción completa

Detalles Bibliográficos
Autores principales: Suh, Minseok, Ryoo, Hyun Gee, Kang, Keon Wook, Jeong, Jae Min, Jeong, Chang Wook, Kwak, Cheol, Cheon, Gi Jeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Radiology 2022
Materias:
Nuclear Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434735/
https://www.ncbi.nlm.nih.gov/pubmed/35762185
http://dx.doi.org/10.3348/kjr.2022.0176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434735/
https://www.ncbi.nlm.nih.gov/pubmed/35762185
http://dx.doi.org/10.3348/kjr.2022.0176

Ejemplares similares